Summary for the risk of neurosensory disability in later childhood in children born to mothers with GDM

No conclusions possible: low‐ to very low‐quality evidence, or insufficient evidence to comment on the effectiveness, more evidence needed Low‐quality evidence suggested no clear evidence of a difference for the risk of any mild developmental delay, hearing or visual impairment in later childhood (18 months) for children born to mothers who had GDM treated with either insulin or oral anti‐diabetic pharmacological therapies